{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:37Z","timestamp":1790960557215,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jtha.2023.09.031","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T01:14:08Z","timestamp":1696986848000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy"],"prefix":"10.1016","volume":"22","author":[{"given":"Gerald","family":"Soff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Leader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Maraveyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.09.031_bib1","unstructured":"Hematopoietic Growth Factors. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae); 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf"},{"key":"10.1016\/j.jtha.2023.09.031_bib2","first-page":"21","article-title":"Dose reductions and delays: limitations of myelosuppressive chemotherapy","volume":"14","author":"Cairo","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jtha.2023.09.031_bib3","first-page":"170","article-title":"Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials","volume":"20","author":"Kilpatrick","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jtha.2023.09.031_bib4","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jtha.2023.09.031_bib5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2023.09.031_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A\u00a0multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.09.031_bib7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","article-title":"Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices","volume":"13","author":"Denduluri","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jtha.2023.09.031_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-014-2416-x","article-title":"The impact of dose\/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer","volume":"73","author":"Nakayama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtha.2023.09.031_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257673","article-title":"Systematic literature review and meta-analysis on use of thrombopoietic agents for chemotherapy-induced thrombocytopenia","volume":"17","author":"Soff","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.09.031_bib10","unstructured":"CTEP. CTEP cancer therapy evaluation program; 2022. https:\/\/ctep.cancer.gov\/"},{"key":"10.1016\/j.jtha.2023.09.031_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet transfusion for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2023.09.031_bib12","first-page":"CD010983","article-title":"Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"2015","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2023.09.031_bib13","first-page":"1558","article-title":"Issues in the management of cancer-related thrombocytopenia","volume":"16","author":"Goodnough","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jtha.2023.09.031_bib14","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1111\/trf.15414","article-title":"Implementation of a patient blood management program in hematopoietic stem cell transplantation (Editorial, p. 2763)","volume":"59","author":"Warner","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2023.09.031_bib15","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2023.09.031_bib16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/bjh.16658","article-title":"Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry","volume":"190","author":"Mytych","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","article-title":"Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy","volume":"146","author":"Afdhal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2023.09.031_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib19","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib20","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A\u00a0randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtha.2023.09.031_bib21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib22","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2023.09.031_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12701","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use","volume":"6","author":"Wilkins","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.031_bib24","doi-asserted-by":"crossref","first-page":"e1799","DOI":"10.1212\/WNL.0000000000008440","article-title":"Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: the PLATUM trial","volume":"93","author":"Le Rhun","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2023.09.031_bib25","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.1997.15.6.2262","article-title":"Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy","volume":"15","author":"Wetzler","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtha.2023.09.031_bib26","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/10428194.2020.1762878","article-title":"A\u00a0novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia","volume":"61","author":"Strickland","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2023.09.031_bib27","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(18)30231-X","article-title":"Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study","volume":"6","author":"Frey","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib28","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","article-title":"Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial","volume":"5","author":"Mittelman","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib29","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3026(15)00149-0","article-title":"Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1\/2 trial","volume":"2","author":"Platzbecker","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib30","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.bbmt.2019.05.023","article-title":"Thrombopoietin receptor agonists for severe thrombocytopenia after allogeneic stem cell transplantation: experience of the Spanish Group of Hematopoietic Stem Cell Transplant","volume":"25","author":"Bento","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2023.09.031_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ph15040419","article-title":"Efficacy and immunomodulating properties of eltrombopag in aplastic anemia following autologous stem cell transplant: case report and review of the literature","volume":"15","author":"Bortolotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jtha.2023.09.031_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106870","article-title":"Eltrombopag may induce bone marrow fibrosis in allogeneic hematopoietic stem cell transplant recipients with prolonged thrombocytopenia","volume":"118","author":"Bostankolu De\u011firmenci","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtha.2023.09.031_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/tme.12300","article-title":"Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature","volume":"26","author":"Dyba","year":"2016","journal-title":"Transfus Med"},{"key":"10.1016\/j.jtha.2023.09.031_bib34","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1097\/MPH.0000000000001551","article-title":"The successful sequential use of plerixafor and eltrombopag for hematopoietic cell transplantation in a child with high-risk neuroblastoma","volume":"42","author":"Marjanska","year":"2020","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtha.2023.09.031_bib35","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41409-019-0442-3","article-title":"Eltrombopag for post-transplant cytopenias due to poor graft function","volume":"54","author":"Marotta","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2023.09.031_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000487229","article-title":"Use of eltrombopag in improving poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Master","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jtha.2023.09.031_bib37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbmt.2016.01.018","article-title":"Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation","volume":"22","author":"Tanaka","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2023.09.031_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13962","article-title":"Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: single-centre experience","volume":"25","author":"Yaman","year":"2021","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtha.2023.09.031_bib39","doi-asserted-by":"crossref","first-page":"430.e1","DOI":"10.1016\/j.jtct.2021.02.004","article-title":"Eltrombopag for post-transplantation thrombocytopenia: results of phase II randomized, double-blind, placebo-controlled trial","volume":"27","author":"Ahmed","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtha.2023.09.031_bib40","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/bloodadvances.2022007838","article-title":"Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.09.031_bib41","article-title":"A\u00a0real-world observation of eltrombopag and recombinant human thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtha.2023.09.031_bib42","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.09.031_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103581","article-title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: a systematic review and meta-analysis","volume":"171","author":"Tjepkema","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtha.2023.09.031_bib44","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial","volume":"140","author":"Gernsheimer","year":"2022","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:38:56Z","timestamp":1761536336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623007341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1538783623007341"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.031","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}